Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative); F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto; Professor in the Faculties of Medicine and Pharmacy, University of Toronto; Senior Scientist at the Toronto General Hospital Research Institute; and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. He completed a Master's Degree in Clinical Epidemiology at McMaster University, and a Clinical Fellowship in Medical Decision Making at the New England Medical Centre in Boston. Dr. Krahn's research program focuses on the use of decision analytic methods to examine health policy and health decision-making. He leads one of the leading technology assessment institutes in the country.
Murray D Krahn
My central area of research interest has been the application of decision analysis and economic evaluation to broad questions of health and clinical policy. This methodologic focus has been expressed in a variety of content areas including prostate cancer and viral hepatitis. More recent interests include evaluating the role of disease specific utility assessment, using administrative data to build longitudinal cost models, and evaluating the role of health technology assessment in pharmaceutical reimbursement decisions.
CMAJ Open. 2017 Aug 25;5(3):E662-E672
Health Policy. 2017 Jun 24;:
Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
BMC Public Health. 2017 Jun 26;17(1):596
Pediatr Blood Cancer. 2017 May 13;:
Changes in blood pressure among patients in the Ontario Telehomecare programme: An observational longitudinal cohort study.
J Telemed Telecare. 2017 Jan 01;:1357633X17706286
Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.
Pharmacoeconomics. 2017 Apr 21;:
CMAJ Open. 2017 Jan-Mar;5(1):E97-E108
J Wound Care. 2017 Apr 01;26(sup4):S4-S14
Costs for Childhood and Adolescent Cancer, 90 Days Prediagnosis and 1 Year Postdiagnosis: A Population-Based Study in Ontario, Canada.
Value Health. 2017 Mar;20(3):345-356
Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison.
Healthc Policy. 2017 Feb;12(3):95-108
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Director of THETA (Toronto Health Economics and Technology Assessment Collaborative)
F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto
Professor in the Faculties of Medicine and Pharmacy, University of Toronto
Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto.